ReveraGen BioPharma has received a $3.3 million grant from the NIH – the US National Institutes of Health – for their ongoing work on the steroid alternative treatment Vamorolone for Duchenne muscular dystrophy.

The NIH Commercialization Readiness Pilot Grant will provide additional funding towards ReveraGen’s new drug application (NDA) preparation for Vamorolone in Duchenne.

The Duchenne Research Fund together with Duchenne UK and Joining Jack awarded $1m to ReveraGen to support the Phase 1 trial of Vamorolone.

Click here to learn more about the research we funded.

Click here to read the full press release about the $3.3m award.